Zhou C - Search Results

1

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.

Yang JJ, Fang J, Shu YQ, Chang JH, Chen GY, He JX, Li W, Liu XQ, Yang N, Zhou C, Huang JA, Frigault MM, Hartmaier R, Ahmed GF, Egile C, Morgan S, Verheijen RB, Mellemgaard A, Yang L, Wu YL. Yang JJ, et al. Among authors: zhou c. Invest New Drugs. 2021 Apr;39(2):477-487. doi: 10.1007/s10637-020-01010-4. Epub 2020 Oct 14. Invest New Drugs. 2021. PMID: 33052556 Clinical Trial.

2

Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cells.

Su C, Su B, Tang L, Zhao Y, Zhou C. Su C, et al. Among authors: zhou c. Cancer Invest. 2007;25(7):542-9. doi: 10.1080/07357900701513272. Cancer Invest. 2007. PMID: 17952737

3

Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.

Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C. Zhou S, et al. Among authors: zhou c. Respirology. 2009 Jul;14(5):709-15. doi: 10.1111/j.1440-1843.2009.01564.x. Respirology. 2009. PMID: 19659649 Clinical Trial.

4

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.

Li Z, Zhou S, Zhang L, Su C, Hang J, Zhao Y, Su B, Zhou C. Li Z, et al. Among authors: zhou s, zhou c. Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17. Med Oncol. 2011. PMID: 20237869

5

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J. Ren S, et al. Among authors: zhou s, zhou c. Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26. Cancer Invest. 2010. PMID: 20504223 Clinical Trial.

6

Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.

Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K. Mok T, et al. Among authors: zhou c. J Thorac Oncol. 2010 Oct;5(10):1609-15. doi: 10.1097/JTO.0b013e3181e15d55. J Thorac Oncol. 2010. PMID: 20808255 Free article. Clinical Trial.

7

Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes.

Meng S, Su B, Li W, Ding Y, Tang L, Zhou W, Song Y, Li H, Zhou C. Meng S, et al. Among authors: zhou w, zhou c. Nanotechnology. 2010 Oct 15;21(41):415103. doi: 10.1088/0957-4484/21/41/415103. Epub 2010 Sep 17. Nanotechnology. 2010. PMID: 20852356

8

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Ju L, Zhou C, Li W, Yan L. Ju L, et al. Among authors: zhou c. J Cell Biochem. 2010 Dec 15;111(6):1565-74. doi: 10.1002/jcb.22888. J Cell Biochem. 2010. PMID: 21053345

9

Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy.

Xu ZY, Jin CJ, Zhou CC, Wang ZQ, Zhou WD, Deng HB, Zhang M, Su W, Cai XY. Xu ZY, et al. J Cancer Res Clin Oncol. 2011 Jul;137(7):1117-22. doi: 10.1007/s00432-011-0975-3. Epub 2011 Feb 5. J Cancer Res Clin Oncol. 2011. PMID: 21298288 Clinical Trial.

10

Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.

Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Tsai CM, et al. Among authors: zhou c. J Thorac Oncol. 2011 Jun;6(6):1092-7. doi: 10.1097/JTO.0b013e318216687d. J Thorac Oncol. 2011. PMID: 21512405 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21,030 results

Search Page

Filters